Control Bionics Limited
Control Bionics Limited (CBL.AX) Financial Performance & Income Statement Overview
Analyze Control Bionics Limited (CBL.AX) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Control Bionics Limited (CBL.AX) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Control Bionics Limited CBL.AX financial performance.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $2.90M | $2.39M | $2.96M | $2.74M |
| Cost of Revenue | $1.06M | $659342.00 | $3.79M | $3.44M |
| Gross Profit | $1.83M | $1.73M | -$822470.00 | -$698723.00 |
| Gross Profit Ratio | $0.63 | $0.72 | -$0.28 | -$0.25 |
| R&D Expenses | $565956.00 | $1.54M | $170752.00 | $149887.00 |
| SG&A Expenses | $4.32M | $3.76M | $1.71M | $2.16M |
| Operating Expenses | $4.89M | $5.30M | $1.88M | $2.31M |
| Total Costs & Expenses | $5.95M | $5.96M | $5.67M | $5.75M |
| Interest Income | $0.00 | $10762.00 | $6802.00 | $18544.00 |
| Interest Expense | $0.00 | $82018.00 | $15274.00 | $0.00 |
| Depreciation & Amortization | $451276.00 | $511068.00 | $255112.00 | $255456.00 |
| EBITDA | -$2.68M | -$3.27M | -$2.45M | -$2.75M |
| EBITDA Ratio | -$0.93 | -$1.37 | -$0.83 | -$1.004 |
| Operating Income | -$3.05M | -$3.57M | -$2.70M | -$3.010M |
| Operating Income Ratio | -$1.05 | -$1.50 | -$0.91 | -$1.10 |
| Other Income/Expenses (Net) | -$381881.00 | -$149786.00 | $30895.00 | $379965.00 |
| Income Before Tax | -$3.44M | -$3.72M | -$2.67M | -$2.63M |
| Income Before Tax Ratio | -$1.19 | -$1.56 | -$0.90 | -$0.96 |
| Income Tax Expense | -$214217.00 | $0.00 | -$483301.00 | $4.00 |
| Net Income | -$3.22M | -$3.72M | -$2.19M | -$2.63M |
| Net Income Ratio | -$1.11 | -$1.56 | -$0.74 | -$0.96 |
| EPS | -$0.01 | -$0.02 | -$0.02 | -$0.03 |
| Diluted EPS | -$0.01 | -$0.02 | -$0.02 | -$0.03 |
| Weighted Avg Shares Outstanding | $231.81M | $212.48M | $106.32M | $100.32M |
| Weighted Avg Shares Outstanding (Diluted) | $231.81M | $212.47M | $106.32M | $100.32M |
Over the last four quarters, Control Bionics Limited's revenue moved from $2.74M in Q4 2023 to $2.90M in Q2 2025. Operating income in Q2 2025 was -$3.05M, with a strong operating margin of -105%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Control Bionics Limited remained robust at -$2.68M, reflecting operational efficiency. Net income rose to -$3.22M, with an EPS of -$0.01. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan